Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & ...
A recently approved injectable eczema drug provides quick itch relief to patients with the maddening skin disease, a new ...
A recently approved injectable eczema drug, Nemluvio, provides quick itch relief to patients with the maddening skin disease, ...
Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...
Due to eczema, asthma and allergies being so closely connected, coordinated care plays a critical role in long-term outcomes. Allergists are uniquely trained to manage these conditions together rather ...
HealthDay News — Iron deficiency without anemia is a common feature of moderate-to-severe atopic dermatitis (AD), according to a study published in Nutrients.
A new study published in the journal of Inflammopharmacology showed that in individuals with moderate-to-severe atopic ...
A recent study revealed that iron deficiency without anemia is common among adults with moderate-to-severe atopic dermatitis ...
Stocktwits on MSN
Johnson & Johnson terminates experimental eczema drug study after it fails to show benefit
The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study. ・JNJ, ...
Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...
In 2025, the most-read Healio story on skin disorders was about the impact dietary diversity during pregnancy has on the risk ...
“Parents need to be reassured that if their baby is allergic to peanut, they may see hives, some swelling, or vomiting, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback